Pfizer (PFE) Capital Expenditures (2009 - 2026)

Pfizer (PFE) has 18 years of Capital Expenditures data on file, last reported at $436.0 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $436.0 million, down 22.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 billion (down 35.82% YoY), and the FY2025 annual result was $2.6 billion, down 9.63% from the prior year.
• Capital Expenditures fell to $436.0 million in Q1 2026 per PFE's latest filing, from $845.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $2.2 billion in Q4 2022 and troughed at $436.0 million in Q1 2026.
• A 5-year average of $928.9 million and a median of $751.0 million in 2022 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures soared 145.93% in 2024, then tumbled 69.78% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $2.2 billion in 2022, then slumped by 53.29% to $1.0 billion in 2023, then surged by 90.8% to $2.0 billion in 2024, then tumbled by 57.58% to $845.0 million in 2025, then tumbled by 48.4% to $436.0 million in 2026.
• Business Quant data shows PFE's Capital Expenditures at $436.0 million in Q1 2026, $845.0 million in Q4 2025, and $602.0 million in Q3 2025.